Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...

INmune Bio Inc. (NASDAQ: INMB) (the 'Company”), a clinical-stage inflammation and immunology company, today announced that it ...